SG11201402673YA - Robust controlled-release formulations - Google Patents

Robust controlled-release formulations

Info

Publication number
SG11201402673YA
SG11201402673YA SG11201402673YA SG11201402673YA SG11201402673YA SG 11201402673Y A SG11201402673Y A SG 11201402673YA SG 11201402673Y A SG11201402673Y A SG 11201402673YA SG 11201402673Y A SG11201402673Y A SG 11201402673YA SG 11201402673Y A SG11201402673Y A SG 11201402673YA
Authority
SG
Singapore
Prior art keywords
release formulations
robust controlled
robust
controlled
formulations
Prior art date
Application number
SG11201402673YA
Inventor
Fredrik Tiberg
Markus Johnsson
Original Assignee
Camurus Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47226199&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201402673Y(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Camurus Ab filed Critical Camurus Ab
Publication of SG11201402673YA publication Critical patent/SG11201402673YA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/09Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1274Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
SG11201402673YA 2011-12-05 2012-11-28 Robust controlled-release formulations SG11201402673YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161566851P 2011-12-05 2011-12-05
PCT/EP2012/073843 WO2013083460A1 (en) 2011-12-05 2012-11-28 Robust controlled-release formulations

Publications (1)

Publication Number Publication Date
SG11201402673YA true SG11201402673YA (en) 2014-06-27

Family

ID=47226199

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201402673YA SG11201402673YA (en) 2011-12-05 2012-11-28 Robust controlled-release formulations

Country Status (23)

Country Link
US (2) US9585959B2 (en)
EP (2) EP2787974B1 (en)
JP (2) JP6081480B2 (en)
KR (2) KR101979051B1 (en)
CN (2) CN104105479B (en)
AU (2) AU2012348640B2 (en)
BR (2) BR112014013693B1 (en)
CA (2) CA2858227C (en)
CL (1) CL2014001472A1 (en)
CO (1) CO7000746A2 (en)
DK (2) DK2787975T3 (en)
EA (2) EA027924B1 (en)
ES (2) ES2629188T3 (en)
HK (2) HK1201722A1 (en)
HR (1) HRP20170954T1 (en)
IL (2) IL232789B (en)
MX (2) MX350929B (en)
PE (1) PE20141297A1 (en)
PL (1) PL2787975T3 (en)
SG (1) SG11201402673YA (en)
SI (1) SI2787974T1 (en)
WO (2) WO2013083459A1 (en)
ZA (1) ZA201403793B (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ551990A (en) * 2004-06-04 2011-01-28 Camurus Ab Liquid depot formulations
GB0711656D0 (en) * 2007-06-15 2007-07-25 Camurus Ab Formulations
TWI624271B (en) * 2011-05-25 2018-05-21 凱慕路斯公司 Pre-formulation comprising a low viscosity mixture and its formulation process, and uses of said low viscosity mixture or pre-formulation
SG11201407678YA (en) 2012-05-25 2014-12-30 Camurus Ab Somatostatin receptor agonist formulations
CA2879942C (en) 2012-07-26 2020-06-02 Camurus Ab Opioid formulations
EP2823808A1 (en) * 2013-07-09 2015-01-14 Ipsen Pharma S.A.S. Pharmaceutical composition for a sustained release of lanreotide
AU2014340095A1 (en) 2013-10-22 2016-05-26 Prolynx Llc Conjugates of somatostatin and its analogs
WO2016092569A1 (en) * 2014-12-10 2016-06-16 Council Of Scientific & Industrial Research A discontinuous reverse micellar composition in cubic fd3m phase for sustained release of therapeutic drugs
KR20170099978A (en) * 2014-12-23 2017-09-01 카무러스 에이비 Controlled-release formulation
GB201516554D0 (en) * 2015-09-18 2015-11-04 Camurus Ab Controlled-release formulations
ITUB20160416A1 (en) * 2016-01-28 2017-07-28 Italfarmaco Spa Use of a slow-release formulation of octreotide for the prevention of seroma formation
MX2018011893A (en) * 2016-03-31 2019-01-10 Sun Pharma Advanced Res Co Ltd Viscoelastic gel of liraglutide adapted for once-weekly or once bi-weekly administration.
RU2757903C2 (en) 2016-09-15 2021-10-22 Камурус Аб Prostacyclin analogue preparations
TWI756270B (en) 2016-09-27 2022-03-01 瑞典商凱慕路斯公司 Formulations containing a somatostatin receptor agonist
US10779576B2 (en) 2017-05-24 2020-09-22 VMR Products, LLC Flavor disk
WO2019182745A1 (en) 2018-03-19 2019-09-26 Bryn Pharma, LLC Epinephrine spray formulations
KR20210003877A (en) 2018-05-01 2021-01-12 치비 인코포레이티드 Liquid depot for continuous, non-invasive delivery of drugs to the eye
WO2019213326A1 (en) * 2018-05-01 2019-11-07 Idrop, Inc. Eye drop formulation and method for sustained delivery of medicament to the retina
CN108498849B (en) * 2018-05-08 2021-04-30 武汉百纳礼康生物制药有限公司 Liquid crystal gel hepatic artery embolism agent and preparation method thereof
CN109091451B (en) * 2018-09-10 2021-08-13 武汉百纳礼康生物制药有限公司 Oil phase liquid crystal gel precursor preparation of hydrophilic medicine and preparation method thereof
EP3975991A1 (en) 2019-05-29 2022-04-06 Camurus AB Lipid-controlled release compositions
WO2021160887A1 (en) 2020-02-14 2021-08-19 Immunor As Corona virus vaccine
WO2022093722A1 (en) * 2020-10-27 2022-05-05 Pts Consulting, Llc A liquid injectable composition of donepezil
CN113081954A (en) * 2021-05-25 2021-07-09 南昌大学第二附属医院 Gel drug-loaded patch drug delivery system
JPWO2023008498A1 (en) * 2021-07-27 2023-02-02

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8206744D0 (en) 1982-11-26 1982-11-26 Fluidcarbon International Ab PREPARATION FOR CONTROLLED RELEASE OF SUBSTANCES
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5538739A (en) 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
DK0752855T3 (en) * 1994-03-30 2000-01-03 Gs Dev Ab Use of fatty acid esters as bioadhesive substances
SE518578C2 (en) 1994-06-15 2002-10-29 Gs Dev Ab Lipid-based composition
EP0839525B1 (en) 1996-10-31 2004-08-04 Takeda Chemical Industries, Ltd. Sustained-release preparation
BE1011899A6 (en) * 1998-04-30 2000-02-01 Ucb Sa PHARMACEUTICAL USE gelling.
JP3952617B2 (en) 1998-12-11 2007-08-01 株式会社日立製作所 Exhaust gas purification device, exhaust gas purification method and exhaust gas purification catalyst for internal combustion engine
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
US20080112915A1 (en) * 2003-10-24 2008-05-15 Marianna Foldvari Dna Delivery with Gemini Cationic Surfactants
ES2623881T3 (en) * 2003-11-07 2017-07-12 Camurus Ab Lipid and cationic peptide compositions
GB0401513D0 (en) 2004-01-23 2004-02-25 Camurus Ab Compositions
JP4966018B2 (en) 2004-01-23 2012-07-04 カムルス エービー Ternary non-lamellar lipid composition
NZ551990A (en) 2004-06-04 2011-01-28 Camurus Ab Liquid depot formulations
US20050287180A1 (en) * 2004-06-15 2005-12-29 Chen Andrew X Phospholipid compositions and methods for their preparation and use
CA2594710C (en) 2005-01-14 2011-01-25 Camurus Ab Topical bioadhesive formulations
PL1843746T3 (en) * 2005-01-14 2011-09-30 Camurus Ab Somatostatin analogue formulations
JP5127466B2 (en) 2005-01-21 2013-01-23 カムルス エービー Pharmaceutical lipid composition
CN101217940B (en) 2005-06-06 2013-03-27 卡穆鲁斯公司 Glp-1 analogue formulations
GB0711656D0 (en) 2007-06-15 2007-07-25 Camurus Ab Formulations
GB0716385D0 (en) * 2007-08-22 2007-10-03 Camurus Ab Formulations

Also Published As

Publication number Publication date
US20140329749A1 (en) 2014-11-06
CN104105479A (en) 2014-10-15
CN104093399A (en) 2014-10-08
IL232967A0 (en) 2014-07-31
AU2012348640A1 (en) 2014-07-17
US9555118B2 (en) 2017-01-31
CA2857982A1 (en) 2013-06-13
EA201491005A1 (en) 2014-11-28
CO7000746A2 (en) 2014-07-21
US20140348903A1 (en) 2014-11-27
EA201490921A1 (en) 2014-11-28
BR112014013693A2 (en) 2020-06-30
CA2858227A1 (en) 2013-06-13
CA2858227C (en) 2021-01-05
HK1201735A1 (en) 2015-09-11
IL232789B (en) 2019-11-28
EP2787974A1 (en) 2014-10-15
SI2787974T1 (en) 2017-10-30
ZA201403793B (en) 2017-04-26
ES2629188T3 (en) 2017-08-07
AU2012348641A1 (en) 2014-06-19
PE20141297A1 (en) 2014-10-09
EA027924B1 (en) 2017-09-29
CN104105479B (en) 2018-04-10
HRP20170954T1 (en) 2017-09-22
WO2013083460A1 (en) 2013-06-13
CN104093399B (en) 2018-03-13
EP2787974B1 (en) 2017-05-24
MX350929B (en) 2017-09-26
DK2787975T3 (en) 2017-11-20
MX352024B (en) 2017-11-07
MX2014006624A (en) 2014-09-22
PL2787975T3 (en) 2018-01-31
AU2012348640B2 (en) 2016-07-21
AU2012348641B2 (en) 2016-04-21
IL232789A0 (en) 2014-07-31
BR112014013693B1 (en) 2023-01-31
KR20140111661A (en) 2014-09-19
EA028040B1 (en) 2017-09-29
EP2787975B1 (en) 2017-10-04
US9585959B2 (en) 2017-03-07
BR112014013691A2 (en) 2017-06-13
WO2013083459A1 (en) 2013-06-13
EP2787975A1 (en) 2014-10-15
JP2015500253A (en) 2015-01-05
ES2645345T3 (en) 2017-12-05
HK1201722A1 (en) 2015-09-11
MX2014006625A (en) 2014-09-22
JP6081480B2 (en) 2017-02-15
JP2015505833A (en) 2015-02-26
CL2014001472A1 (en) 2014-11-21
KR101979051B1 (en) 2019-05-15
JP6081479B2 (en) 2017-02-15
KR20140105527A (en) 2014-09-01
DK2787974T3 (en) 2017-07-17

Similar Documents

Publication Publication Date Title
HRP20170954T1 (en) Robust controlled-release peptide formulations
HRP20181896T1 (en) Pharmaceutical formulations
EP2747556A4 (en) Pyrethroid formulations
HK1204973A1 (en) Diclofenac formulations
IL227094B (en) Immunosuppressant formulations
EP2762167A4 (en) Easy-to-take solid preparation
EP2744496A4 (en) Controlled-release formulation
PL2908835T3 (en) Stable formulations
GB201110278D0 (en) Formulations
IL228357A0 (en) Solid preparation
GB201111578D0 (en) Pharmeutical formulations
GB201111013D0 (en) Formulations
GB201107626D0 (en) Formulations
GB201107627D0 (en) Formulations
GB201105410D0 (en) Formulations
GB201105360D0 (en) Formulations
GB201104049D0 (en) Formulations
GB201104048D0 (en) Formulations
GB201102795D0 (en) Formulations
GB201111577D0 (en) Pharmaceutical formulations
GB201206178D0 (en) Formulations